Impact of electrolyte decomposition products on the electrochemical performance of 4 V class K-ion batteries.

In the pursuit of long-life K-ion batteries (KIBs), half-cell measurements using highly reactive K metal counter electrodes are a standard practice. However, there is increasing evidence of electrolyte decomposition by K metal impacting electrode performance. Herein, we systematically explored the K metal-treated electrolytes KPF, KN(SOF) (KFSA), and their combination in ethylene carbonate/diethyl carbonate (EC/DEC), referred to as K-KPF, K-KFSA, and K-KPF:KFSA, respectively, after storage in contact with K metal.

Development of KPF/KFSA Binary-Salt Solutions for Long-Life and High-Voltage K-Ion Batteries.

A series of binary-salt electrolytes of KPF/KN(SOF) (KFSA) in carbonate ester solvents have been developed for high-voltage K-ion batteries by clarifying the effect of salt ratio and different solvents on the physical properties of the electrolyte solutions and electrochemical performance of K-ion batteries. The KPF/KFSA carbonate ester solutions, such as KPF/KFSA ethylene carbonate (EC)/diethyl carbonate (DEC), exhibit higher ionic conductivity than single-salt KPF one, and higher KFSA content results in higher ionic conductivity. The KPF-rich binary-salt electrolytes with KPF/KFSA ratios of ≥3 (mol/mol) provide enough oxidation stability and passivation against Al corrosion at 4.

Non-secretory multiple myeloma with azurophilic granules and vacuoles: an immunological and ultrastructural study.

Cytoplasmic vacuolation was seen in patients with a variety of plasma cell dyscrasia. We report here a case of leukemic non-secretory multiple myeloma with many azurophilic granules. By electron microscopy, the myeloma cells were found to have a well-developed rough endoplasmic reticulum and a clear Golgi apparatus, and azurophilic granules were identified as phagocytic vacuoles.

Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.

Objective: We investigated the acute-phrase and chronic-phase outcomes of patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with or without antecedent mutant tissue-type plasminogen (t-PA) administration.

Methods: Thirty-nine patients with a first AMI within 6 hours of onset were randomly assigned to the treatment group (1,600,000 IU IV monteplase, n = 19) or the nontreatment group (n = 20), followed by PCI. Clinical outcomes were then evaluated.

Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.

Objective: Inflammatory liver damage and viral persistence after hepatitis C virus (HCV) infection are known to be related in host immunity. Suplatast tosilate is an immunomodulator that selectively inhibits type 2 cytokine production by helper T cells. We investigated the efficacy and safety of the administration of suplatast tosilate for patients with HCV infection by examining the level of serum alanine aminotransferase (ALT) and viremia.

[A case of CIDP with diabetes mellitus who had good response to intravenous immune globulin].

A 64 year-old man began to feel numbness on his bilateral feet in 1990. He was diagnosed as diabetes mellitus with a high fasting glucose level of 580 mg/dl in 1993 and he received oral hypoglycemic agents. Since then, his blood glucose levels had been in good control under diet therapy and medication.